Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression

Inclusion Criteria: * Participants who have provided informed consent prior to any study specific procedures. * Participants currently meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for bipolar I disorder as confirmed by the Structured Clinical Interview (SCID) with a current with a current major depressive episode of at least 4 weeks and not exceeding 12 months in duration. * Participants with normal physical examination, laboratory, vital signs, and/or echocardiogram (ECG). * Verified previous manic or mixed episode. * Participants with a total Hamilton Rating Scale for Depression (HAMD)-17 score ≥ 20. * Participants with a HAMD-17 item 1 score ≥ 2. * Participants with a Clinical Global Impression of Severity (CGI-S) score ≥ 4. Exclusion Criteria: * Participants with a DSM-IV-TR diagnosis of an axis I disorder other than bipolar I disorder that was the primary focus of treatment within the previous 6 months. * Women who are pregnant or breast feeding * Participants with Young Mania Rating Scale (YMRS) total score \> 10 * Participants who have dementia, mental retardation, schizophrenia/schizoaffective disorder.